Group 1 - The company, YuanDa Pharmaceutical, has entered into a product cooperation agreement with YouEr Pharmaceutical Technology (Shanghai) Co., Ltd. to commercialize the world's first epinephrine nasal spray, Neffy, for emergency treatment of type I allergic reactions in adults and children [1] - The agreement grants the company exclusive commercialization rights in mainland China and non-exclusive rights in Hong Kong, with plans for local production within 24 months after product approval [1] - YouEr Pharmaceutical focuses on pediatric medicine, aiming to introduce and develop safe and effective pediatric drugs for children in China, leveraging both global imports and local R&D [1] Group 2 - Neffy is the first non-injection treatment product approved by the FDA for type I allergic reactions in 35 years, expected to improve accessibility for severe allergic reaction patients in China and fill a gap in out-of-hospital emergency medication [2] - The company plans to leverage its extensive resources and established channel systems in emergency care to accelerate academic promotion and market education for Neffy, aiming for rapid market penetration in various out-of-hospital settings [2] Group 3 - The cardiovascular emergency rescue sector is a key focus area for the company, addressing both emergency rescue and chronic disease management [3] - The company has over 30 products in this sector, with 14 included in the national emergency medication catalog and 16 in the shortage medication catalog, providing a comprehensive product mix for various emergency scenarios [3] - The company has more than 20 products in development for cardiovascular emergency and chronic disease treatment, combining innovative R&D with complex generic technology breakthroughs [3] Group 4 - The company emphasizes the importance of innovative products and advanced technology development, focusing on unmet clinical needs and increasing investment in global innovations [4] - The strategy involves a "global operation layout and dual circulation development," promoting a new model of domestic and international interlinked development [4] - The company aims to rapidly bring innovative products to market, providing advanced and diverse treatment options for patients worldwide [4]

Core Viewpoint - The company has entered into a product cooperation agreement with Youer Pharmaceutical Technology (Shanghai) Co., Ltd. to commercialize the world's first epinephrine nasal spray, Neffy® (优敏速®), for emergency treatment of type I allergic reactions in adults and children in China [1][2] Group 1: Product Cooperation and Market Potential - The agreement grants the company exclusive commercialization rights in mainland China and non-exclusive rights in Hong Kong for Neffy®, which is expected to enhance accessibility for severe allergic reaction patients [1][2] - Neffy® is the first non-injection treatment product approved by the FDA for type I allergic reactions in 35 years, filling a gap in emergency medication for out-of-hospital scenarios [2] Group 2: Company’s Strategic Focus - The company is focusing on the cardiovascular emergency sector, which includes both emergency rescue and chronic disease management, with over 30 products in its portfolio [3] - The company has a strong presence in the emergency medication market, with 14 products listed in the national emergency medication catalog and 16 in the shortage medication catalog [3] Group 3: Innovation and Development Strategy - The company emphasizes innovation and advanced technology development, aiming to meet unmet clinical needs and enhance its product pipeline through global innovation [4] - The strategy includes a dual-circulation development model that promotes both domestic and international growth, leveraging the company's industrial advantages and research capabilities [4]